Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMG 509 in Metastatic Castration-Resistant Prostate Cancer
NCT04221542Phase 1Recruiting
- Sponsor
- Amgen
- Start
- Mar 2020
- Primary completion
- Mar 2030
- Modality
- Bispecific Antibodies, T-cell Engagers
- Countries
- 10
01
Overview
Phase 1, open-label trial of xaluritamig in prostate cancer (PCa) (7 arms), sponsored by Amgen. Primary endpoints: Incidence of Treatment-emergent Adverse Events at 3 years, Incidence of Treatment-related Adverse Events at 3 years and 2 more. Started Mar 2020; status: recruiting.
02
Drugs
xaluritamig
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT04221542.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04221542.